Fifth Third Bancorp Grows Position in TransMedics Group, Inc. $TMDX

Fifth Third Bancorp raised its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 4,638.5% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 20,802 shares of the company’s stock after acquiring an additional 20,363 shares during the period. Fifth Third Bancorp’s holdings in TransMedics Group were worth $2,068,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. D.A. Davidson & CO. grew its stake in shares of TransMedics Group by 0.5% in the 4th quarter. D.A. Davidson & CO. now owns 15,334 shares of the company’s stock worth $1,865,000 after acquiring an additional 83 shares in the last quarter. Parallel Advisors LLC raised its holdings in shares of TransMedics Group by 42.1% in the fourth quarter. Parallel Advisors LLC now owns 280 shares of the company’s stock valued at $34,000 after purchasing an additional 83 shares during the last quarter. HighPoint Advisor Group LLC lifted its position in shares of TransMedics Group by 3.1% during the fourth quarter. HighPoint Advisor Group LLC now owns 2,955 shares of the company’s stock valued at $359,000 after purchasing an additional 88 shares in the last quarter. Crossmark Global Holdings Inc. lifted its position in shares of TransMedics Group by 4.0% during the fourth quarter. Crossmark Global Holdings Inc. now owns 2,275 shares of the company’s stock valued at $277,000 after purchasing an additional 88 shares in the last quarter. Finally, Canada Pension Plan Investment Board boosted its holdings in TransMedics Group by 2.9% during the second quarter. Canada Pension Plan Investment Board now owns 3,600 shares of the company’s stock worth $482,000 after purchasing an additional 100 shares during the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

TransMedics Group Stock Performance

NASDAQ TMDX opened at $74.29 on Wednesday. TransMedics Group, Inc. has a 52-week low of $60.10 and a 52-week high of $156.00. The company has a 50-day simple moving average of $71.23 and a 200 day simple moving average of $103.78. The company has a debt-to-equity ratio of 1.70, a quick ratio of 6.19 and a current ratio of 6.74. The company has a market capitalization of $2.57 billion, a PE ratio of 16.88 and a beta of 1.89.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings data on Tuesday, May 5th. The company reported $0.30 EPS for the quarter, missing the consensus estimate of $0.62 by ($0.32). The company had revenue of $173.93 million during the quarter, compared to the consensus estimate of $174.44 million. TransMedics Group had a return on equity of 22.38% and a net margin of 27.04%.The business’s revenue was up 21.2% on a year-over-year basis. During the same period in the prior year, the firm posted $0.70 EPS. On average, research analysts predict that TransMedics Group, Inc. will post 1.88 EPS for the current year.

Insider Activity

In related news, Director Thomas J. Gunderson sold 9,624 shares of TransMedics Group stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $75.06, for a total value of $722,377.44. Following the sale, the director owned 16,642 shares of the company’s stock, valued at approximately $1,249,148.52. The trade was a 36.64% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 6.90% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on TMDX. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $124.00 price objective on shares of TransMedics Group in a research report on Tuesday, June 30th. Weiss Ratings reissued a “hold (c)” rating on shares of TransMedics Group in a research report on Tuesday, June 9th. Wall Street Zen downgraded TransMedics Group from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Needham & Company LLC reduced their target price on TransMedics Group from $174.00 to $142.00 and set a “buy” rating for the company in a report on Wednesday, May 6th. Finally, Oppenheimer lowered TransMedics Group from an “outperform” rating to a “market perform” rating in a report on Wednesday, May 6th. Six investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, TransMedics Group presently has a consensus rating of “Hold” and a consensus price target of $134.50.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.